9999999997-23-004516.txt : 20231010
9999999997-23-004516.hdr.sgml : 20231010
20231010170002
ACCESSION NUMBER: 9999999997-23-004516
CONFORMED SUBMISSION TYPE: SEC STAFF ACTION
CATEGORY: ORDER
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20231010
ACTION DATE: 20231010
RECEIVED DATE: 20231010
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: GENEREX BIOTECHNOLOGY CORP
CENTRAL INDEX KEY: 0001059784
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 820490211
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0731
FILING VALUES:
FORM TYPE: SEC STAFF ACTION
BUSINESS ADDRESS:
STREET 1: 10102 USA TODAY WAY
CITY: MIRAMAR
STATE: FL
ZIP: 33025
BUSINESS PHONE: 416-364-2551
MAIL ADDRESS:
STREET 1: 10102 USA TODAY WAY
CITY: MIRAMAR
STATE: FL
ZIP: 33025
ORDER
1
filename1.pdf
begin 644 filename1
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MD=W)G##GBG"'BRY_"SITE34=JX8*(:UC5K1#G'8M[)"WS"'1[I(I
M+Y%BITL#/P^GAQ<=WQ]J0=3*(V*/FL!5JIBYCGM&*E>IZ3FU9GW\/"7%@R2+
MN"@@DK.]'0USH?)YR@9N]VW)#T.$%RI?#-N(7KD0@5Q(_0QWLO9V$,5WCU*!
M0BI?6V.4%\D^WA;DNM/RUZH9<_(+0+\Q/I\J3(-HK8ZMJ]8@FJB'=1$:3))O
MZFF=Z5IX
6>HJ!+?OY&IS.5?Y#K)"KE]2+/'[/Y,QEG^
M)1WLVQ+#7D
M5<'H6ZJQ(6X^#1A%AD&.):(AWWE4+60^]7R*-&>.I9KZ\(>OIS7P3K4?1R]AS2\=EOQ >TB\$WKL\$5++G>.S
M<2= ) ?;2AI((<1;+D(6<%L]
M9NWSVC#=.N7L4='XR7;'*@]+AMI.W#D8L/G!X/:M;-5/Y_!N3&'G8&.COI
M;W6F^)S;2)=,<:*6I.'^!='.]:-1P(S8QV(7'T(]9_BL^
M.N+'SA3(F:++9=I;8Y1T+?EOE4=RN"VOA02^DF+X71A7/'P1]_#U5&EH^?]=
M_WEU9OV^AYJV(T])\5 M/./L<$B.1WA#8I++^^18/ N28Q$7LORZS=)5A%.V
M*05)QPDEAUF8X<5!:?2+[ 4'[&%'N3WE29'((SFE.WBPD=L*G/^Y'W]^ WM:
M16*CQ$;09>!IV1DIB>#=O^/$:,@U,#I"&,,""R>\;"F-_D-\)'=2I@0PE X@
M^RPGARR7 !\,I4DJX9]I\7 D<;HCI7B:%>0L"U#;9@=)Y'Y?4O\F*0[==6'U
M#$V4QK2HA[17URWSJ7LY1'IXI7 %I]QR&7B>*XW_'+K5M>SC*GZK(#E^R=+J
M5[BK9"M?0F1]@OMU@["\VH[8]75,.E &/<)"#:\<2J-?6 ../&6GQQUXD^SD
M]C'.@4-\![[.4OCME#[*XY$D( 44B^0@'\\D!K4=O,QRB\?#IQ'?-@0HDZJ)@4_UDC%+TCC=RBORY90?3S$X#W"BU6NLW/04'AUD&?P66GAF*8U^?"H>,NA39XN'&.2R$.89EHG\0E0_$395
MWJSWYK;FX^.)J=*QKAF"K^UK09/FVJX1X'G.W4!#8%QL@.>YTGC]VZ&6_?;^
M$R ))QP8;#IA(3-\6TE#MCG]':?0YC_$9WG$88H@I,R]A'IQK]@>'.!YR(5G
M)8#GH=+XH7O5[5_<*Y(2+U?4 0L)T;:2AFRUWY>]?_R0R+WE6GV/#A&D^**K
M(MS&\CG0_P&VC.Q&"F5N9'-T'2N(#4N-"XU(*DR,# P+3(P,3,@,50S6%0@0E9"02!<*$%'
M4$PM=F5R)RE6-MNXS80_17^0"&1,QR2P") D]U%B\4606*@#T8>G$0(#"3V(K87
M[=_W4"-?F+H*E0:!*%ESSID9#B\BF=:(L>R,)>,L;L6X9$VTAH1-),-M:R*;
MY,5XDX(8-K9UWD0T> K&6CS9%BT>D[$N/X+/A?P.O XM?J* E[AE@BU(&!H6
M/WENC<-/'K(./TEV!NR2X!'L@T_&X3E"P\$^"GR#?8((90II#3E0M-$X>-_"
M4[C@++-Q^+$S+Z2] (16\@/X);'A
M[))O#5QTL;6&81*]-UDJMQBFY \M,@#0\*"AR%ID4V?78:XAYV+
MP?@L"7&&JQ2300C$X,4_><%[N"Q(4@Y!@C;!'^%?#BF!!%V'
M?B,CN?\B[!U< C]"9(N\"J0
M!I\ %Q!B0/PYM #R7!81%80NY@C2D$-!)\)53B 3N-KF/*(!#1QV2,&G3\UL
M<;]I;INK]6K;K;8;$UL4Y$TS^_M'UUPOGKKFIMNL=Z\/W0;&7V&5&XN2S59?
M^ZKM[R@7+NXN\-?<;E]W#]OKQ6M/V39ZEVLZVW[O'I>+R_5?\RPEZ.R0W-W%
M1?;F=G>_S-R]=3\N5S]NMHL
M]\^3F&[6+XO5_Z7ZK7O^V6V7#XMWB+XM'S?S/E]WQP1OD/L=DF-A,W?Y)09X
MOOK^&OIK[*^IO]I6&ZN-0JQBK(*LHJS"K.*6;RR
M>&7QRN*')"J+EW.--AA$44M*:^Q:JP=#^O8'*OOZR=!Q0.NX
M_/+^T(C5&KP)(U8:*1*#9FDH:/G(**CJ$(E3E-QI4IM
MG]AV.L1.\^QTAC@Z&&O5:#J$IT/\M)C.3'"'T'0RJQD/=CK$38?0OR!CL6%F
MGFCO)]H?AX^OR77UHG#L@'TE?U[^'&66$D8#;/9Y%%5.3%0]^Z4#A&KBICVQ@:-][NL87LE'TL_E[,K5^\$
MIFTWN"PMKMT,,$^'^.F0:7N.<_O40VC>UXF")=L7[[]?X6OJZO?/H+ZX&'F+
MW!_UN,KELCS\?GIX9P[W_FQ5O8?B4JRR&^#D2,QA-"/Q-".Q)B-2;AQ]J(PM
M?2@C9?D+569$W'_'+'02LU05KI0=([;.>SD_M;^'*L>%5,XL?)V796^%VEU62%.%TH?2,7SXQ[,U]>X:O3]A*"?CP^!=
M/^Q>NM5V=/E5@OXZG#H-QTW#.=.P_1^V%,-ISG!&,QS.#.0P_Y[/P-M\OFC^ 9#Y\+D*96YD)PET=560F$4A=']8QS$P X,[.[&Q"X,](%\)=_P..9@
M7$